Wuhan Hiteck Biological Pharma Co.,Ltd (SZSE: 300683)
Health Care · Biotechnology · CN
CN¥29.10
-4.90% today · -51.0% 1Y
Wuhan Hiteck Biological Pharma Co.,Ltd (SZSE: 300683) operates in the Biotechnology industry within the Health Care sector. The company is valued at $566.62M and employs 958 people.
Over the last twelve months the share price has lost 51.0%, trading between 22.58 and 61.76.
Tweenvest scores Wuhan Hiteck Biological Pharma Co.,Ltd across four factors: quality 66/100, value 54/100, growth 0/100. Its strongest factor is quality.
300683 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $566.62M
- Revenue (TTM)
- $78.84M
- P/E
- —
- EPS
- -1.83
- Dividend yield
- —
- Beta (5Y)
- -0.33
- 52-week high
- CN¥61.76
- 52-week low
- CN¥22.58
- Avg volume (3M)
- —
- Shares outstanding
- 130.89M
- Employees
- 958
- Next earnings
- —
About Wuhan Hiteck Biological Pharma Co.,Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.
- ISIN
- CNE1000034C5
- Founded
- 1992
- Listed since
- Aug 8, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €880.20 | -2.42% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.